Mintz, Cohn, Ferris, Glovsky and Popeo P.C. advised BeiGene, Ltd. (NASDAQ:BGNE) on the company’s strategic collaboration with Celgene Corporation (NASDAQ:CELG) to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317.
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics aimed at having both a meaningful and lasting impact on cancer patients. The collaboration will allow BeiGene to further expand its offering for patients with solid tumor cancers in the United States, Europe, Japan and rest of world outside Asia.
Celgene Corporation is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Terms of the deal grant BeiGene exclusive rights for the development and commercialization of BGB-A317 for hematological malignancies globally and for solid tumors in Asia (except Japan). BeiGene will acquire Celgene’s commercial operations in China and gain an exclusive license to commercialize Celgene’s approved therapies in China – ABRAXANE®, REVLIMID® and VIDAZA®.
BeiGene’s legal team was led by Life Sciences Members John Cheney and Susan Foster, PhD.